CTLT - Catalent, Inc.
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Somerset,
United States
Type: Equity
CTLT price evolution
CTLT
| (in millions $) | 1 May 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $229 | $209 | ||
| Short term investments | ||||
| Net receivables | $843 | $830 | $977 | |
| Inventory | $775 | $796 | $764 | |
| Total current assets | $2570 | $2614 | $2679 | |
| Long term investments | ||||
| Property, plant & equipment | $3777 | $3723 | $3699 | |
| Goodwill & intangible assets | $3262 | $3258 | ||
| Total noncurrent assets | $7418 | $7409 | ||
| Total investments | ||||
| Total assets | $9988 | $10023 | $10782 | |
| Current liabilities | ||||
| Accounts payable | $407 | $367 | $427 | |
| Deferred revenue | ||||
| Short long term debt | $46 | $624 | ||
| Total current liabilities | $1036 | $1534 | $1507 | |
| Long term debt | $4959 | $4322 | $4313 | |
| Total noncurrent liabilities | $5265 | $4648 | ||
| Total debt | $5005 | $4946 | ||
| Total liabilities | $6301 | $6182 | $6147 | |
| Shareholders' equity | ||||
| Retained earnings | -$703 | -$497 | $262 | |
| Other shareholder equity | -$354 | -$388 | $4635 | |
| Total shareholder equity | $3687 | $3841 | ||
| (in millions $) | 30 Jul 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $449 | $896 | $953.2 | |
| Short term investments | $89 | $71 | ||
| Net receivables | $977 | $1051 | $1012 | $838.1 |
| Inventory | $764 | $702 | $563 | $323.8 |
| Total current assets | $2679 | $2916 | $2918 | $2293 |
| Long term investments | ||||
| Property, plant & equipment | $3699 | $3127 | $2524 | $1900.8 |
| Goodwill & intangible assets | $4066 | $3336 | $3359.3 | |
| Total noncurrent assets | $7591 | $6194 | $5483.5 | |
| Total investments | $89 | $71 | ||
| Total assets | $10782 | $10507 | $9112 | $7776.5 |
| Current liabilities | ||||
| Accounts payable | $427 | $421 | $385 | $321 |
| Deferred revenue | ||||
| Short long term debt | $31 | $75 | $72.9 | |
| Total current liabilities | $1507 | $1072 | $1196 | $893.2 |
| Long term debt | $4313 | $4171 | $3166 | $2945.1 |
| Total noncurrent liabilities | $4640 | $3642 | $3377.9 | |
| Total debt | $4202 | $3241 | $3018 | |
| Total liabilities | $6147 | $5712 | $4838 | $4271.1 |
| Shareholders' equity | ||||
| Retained earnings | $262 | $538 | $25 | -$535.2 |
| Other shareholder equity | $4635 | -$394 | -$317 | -$386.3 |
| Total shareholder equity | $4795 | $3915 | $2898.8 | |
| (in millions $) | 1 May 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1024 | $982 | $1068 | |
| Cost of revenue | $853 | $813 | ||
| Gross Profit | $171 | $169 | $235 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $250 | $205 | ||
| Total operating expenses | $283 | $895 | $335 | |
| Operating income | -$112 | -$726 | ||
| Income from continuing operations | ||||
| EBIT | -$116 | -$739 | ||
| Income tax expense | $24 | -$38 | -$64 | |
| Interest expense | $66 | $58 | -$54 | |
| Net income | ||||
| Net income | -$206 | -$759 | -$86 | |
| Income (for common shares) | -$206 | -$759 | ||
| (in millions $) | 30 Jul 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4276 | $4828 | $3998 | $3094.3 |
| Cost of revenue | $3188 | $2646 | $2111 | |
| Gross Profit | $1060 | $1640 | $1352 | $983.3 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $844 | $687 | $577.9 | |
| Total operating expenses | $987 | $885 | $706 | $588.9 |
| Operating income | $755 | $646 | $394.4 | |
| Income from continuing operations | ||||
| EBIT | $728 | $825 | $386.5 | |
| Income tax expense | -$83 | $86 | $130 | $39.7 |
| Interest expense | -$184 | $123 | $110 | $126.1 |
| Net income | ||||
| Net income | -$232 | $519 | $585 | $220.7 |
| Income (for common shares) | $503 | $529 | $173 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$206 | -$759 | -$227 | |
| Operating activities | ||||
| Depreciation | $121 | $112 | $106 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16 | $19 | $6 | |
| Total cash flows from operations | $112 | -$70 | -$64 | |
| Investing activities | ||||
| Capital expenditures | -$94 | -$83 | -$137 | |
| Investments | -$1 | -$1 | $27 | |
| Total cash flows from investing | -$95 | -$84 | -$955 | -$110 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1 | $3 | ||
| Net borrowings | $13 | $80 | -$54 | |
| Total cash flows from financing | -$14 | $98 | $521 | -$25 |
| Effect of exchange rate | $17 | -$15 | $11 | $9 |
| Change in cash and equivalents | $20 | -$71 | -$169 | -$190 |
| (in millions $) | 30 Jul 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $519 | $585 | $220.7 | |
| Operating activities | ||||
| Depreciation | $378 | $289 | $253.7 | |
| Business acquisitions & disposals | -$1199 | $140 | -$358.9 | |
| Stock-based compensation | $54 | $51 | $48.1 | |
| Total cash flows from operations | $439 | $433 | $440.3 | |
| Investing activities | ||||
| Capital expenditures | -$660 | -$686 | -$465.8 | |
| Investments | -$22 | -$103 | -$2.8 | |
| Total cash flows from investing | -$955 | -$1884 | -$649 | -$827.5 |
| Financing activities | ||||
| Dividends paid | -$4 | -$22 | -$36.2 | |
| Sale and purchase of stock | $26 | $120 | $1046.5 | |
| Net borrowings | $1022 | $99 | $48.3 | |
| Total cash flows from financing | $521 | $1031 | $142 | $1001.7 |
| Effect of exchange rate | $11 | -$33 | $17 | -$6.7 |
| Change in cash and equivalents | -$169 | -$447 | -$57 | $607.8 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |